Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04321603
Other study ID # HP-00089501
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date May 30, 2020
Est. completion date May 30, 2020

Study information

Verified date August 2021
Source University of Maryland, Baltimore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

People living with HIV are living longer as their disease is controlled with antiretroviral medications. Yet they are experiencing frailty more often and more than ten years earlier than those without HIV. In elderly persons without HIV, frailty is associated with decreased muscle strength and chronic inflammation. Less is known about what is driving early frailty in HIV or effective prevention measures for aging adults with HIV. It may be that having HIV infection impairs energy production by mitochondria within the cells and contributes to the muscle weakness and inflammation accompanying frailty in people living with HIV . This study will examine the impact of six weeks of moderately paced walking on energy production in the cells, inflammation markers and frailty scores in people living with well-controlled HIV who are aged 50 to 65.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 30, 2020
Est. primary completion date May 30, 2020
Accepts healthy volunteers No
Gender All
Age group 50 Years to 65 Years
Eligibility Inclusion Criteria: - Adults aged 50 to 65 - Documentation of HIV infection from Medical Provider - Currently receiving antiretrovirals - HIV viral load less than 50 iu/mL for at least six months - CD4 count at least 350 cell/mm3 for the last six months - Willing and able to walk at least 30 minutes 3 times weekly within 30 minutes of UMB - Speaks English Exclusion Criteria: - Current smokers - Weight less than 110 pounds - Subjects taking long-term corticosteroids equivalent to 10mg/day or more, or immunomodulators - Subjects with conditions known to affect inflammatory or mitochondrial function other than HIV, such as rheumatoid arthritis, gout, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, diabetes, Parkinson's disease, Alzheimer's disease, active hepatitis, sleep apnea or autoimmune diseases. - Current drug or alcohol use or dependence or unstable mental health conditions that, in the opinion of the investigator, would interfere with adherence to study requirements

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Walking
Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Maryland, Baltimore

Outcome

Type Measure Description Time frame Safety issue
Other Frailty Related Phenotype Change in frailty phenotype score (0-5 with 3 to 5 indicating frailty) after a six-week walking intervention Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Primary Mitochondrial Respiration PBMC and platelets Change in mitochondrial respiratory capacity after a six-week walking intervention Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Secondary Inflammation IL-1ß Change in IL-1ß after a six-week walking intervention Day 0, Week 6, Week 12 with intervention between weeks 6 and 12 months
Secondary Inflammation IL-6 Change in IL-6 after a six-week walking intervention Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Secondary Inflammation IL-10 Change in IL-10 after a six-week walking intervention Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Secondary Inflammation TNF-a Change in TNF-a after a six-week walking intervention Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
Secondary Inflammation hsCRP Change in hsCRP after a six-week walking intervention Day 0, Week 6, Week 12 with intervention between weeks 6 and 12
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2